Quick Answer
BELITE BIO, INC reported Net Income of -$77.61 million for fiscal year 2025.
BELITE BIO, INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$77.61M -114.7% |
-$36.14M -14.3% |
-$31.63M -150.1% |
-$12.65M -30.9% |
-$9.67M -68.0% |
-$5.75M |
| Diluted EPS | -$2.31 -95.8% |
-$1.18 +0.8% |
-$1.19 -88.9% |
-$0.63 +37.6% |
-$1.01 -55.4% |
-$0.65 |
| Total Assets | $780.56M +413.1% |
$152.13M +60.7% |
$94.64M +113.8% |
$44.27M +141.3% |
$18.35M | — |
| Cash and Equivalents | $352.93M +1014.2% |
$31.68M -64.1% |
$88.16M +109.5% |
$42.09M +142.7% |
$17.34M | — |
| Stockholders Equity | $770.49M +428.4% |
$145.82M +61.3% |
$90.43M +117.9% |
$41.50M +375.0% |
-$15.09M -114.5% |
-$7.04M -88.2% |
| R&D Expense | $45.38M +51.6% |
$29.94M +20.5% |
$24.84M +180.1% |
$8.87M +19.5% |
$7.42M +101.2% |
$3.69M |
| Operating Income | -$84.21M -110.5% |
-$40.00M -26.3% |
-$31.67M -147.0% |
-$12.82M -30.9% |
-$9.80M -70.6% |
-$5.74M |
| Shares Outstanding | 39.34M +23.6% |
31.83M +9.2% |
29.15M +17.1% |
24.90M +142.3% |
10.27M | — |
- BELITE BIO, INC reported Net Income of -$77.61 million for fiscal year 2025.
- BELITE BIO, INC showed a decrease of -114.7% in Net Income compared to the prior fiscal year.
- BELITE BIO, INC reported Diluted EPS of $2.31 per share (loss) for fiscal year 2025.
- BELITE BIO, INC showed a decrease of -95.8% in Diluted EPS compared to the prior fiscal year.
- BELITE BIO, INC reported Total Assets of $780.56 million for fiscal year 2025.
- BELITE BIO, INC showed an increase of +413.1% in Total Assets compared to the prior fiscal year.
- BELITE BIO, INC reported Cash and Equivalents of $352.93 million for fiscal year 2025.
- BELITE BIO, INC showed an increase of +1014.2% in Cash and Equivalents compared to the prior fiscal year.
- BELITE BIO, INC reported Stockholders Equity of $770.49 million for fiscal year 2025.
- BELITE BIO, INC showed an increase of +428.4% in Stockholders Equity compared to the prior fiscal year.
- BELITE BIO, INC reported R&D Expense of $45.38 million for fiscal year 2025.
- BELITE BIO, INC showed an increase of +51.6% in R&D Expense compared to the prior fiscal year.
- BELITE BIO, INC reported Operating Income of -$84.21 million for fiscal year 2025.
- BELITE BIO, INC showed a decrease of -110.5% in Operating Income compared to the prior fiscal year.
- BELITE BIO, INC reported Shares Outstanding of 39.34 million shares for fiscal year 2025.
- BELITE BIO, INC showed an increase of +23.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: